HC Wainwright & Co. Reiterates Buy on Verrica Pharmaceuticals, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and maintained a $12 price target.
October 12, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verrica Pharmaceuticals (NASDAQ:VRCA) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $12.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Verrica Pharmaceuticals. The maintained price target of $12 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100